Sihui Zhu

321 Zhongshan Road
Nanjing, 210008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Multidimensional analysis of tumour immune microenvironment in HCC: prognostic significance and implications for immunotherapy.

Multidimensional analysis of tumour immune microenvironment in HCC: prognostic significance and implications for immunotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: January 13, 2026

The safety and efficacy of in situ vaccine FOLactis for advanced hepatic malignancies.

The safety and efficacy of in situ vaccine FOLactis for advanced hepatic malignancies.

Journal: Vaccine

Published: December 02, 2025

Intracavitary infusion of FOLactis Lactobacillus leads to disappearance of MPE in patient with advanced lung adenocarcinoma.

Intracavitary infusion of FOLactis Lactobacillus leads to disappearance of MPE in patient with advanced lung adenocarcinoma.

Journal: Discover oncology

Published: June 04, 2025

Nomograms predicting benefit after immunotherapy in oral bifidobacteria supplementation ICC patients: a retrospective study.

Nomograms predicting benefit after immunotherapy in oral bifidobacteria supplementation ICC patients: a retrospective study.

Journal: BMC cancer

Published: July 09, 2024

KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer.

KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer.

Journal: BMC cancer

Published: December 20, 2023

An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy.

An Advanced Intrahepatic Cholangiocarcinoma Patient Benefits from Personalized Immunotherapy.

Journal: Inflammation

Published: November 30, 2023

Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy.

Lymphocyte-to-C Reactive Protein Ratio is an Independent Predictor of Survival Benefits for Hepatocellular Carcinoma Patients Receiving Radiotherapy.

Journal: Journal of hepatocellular carcinoma

Published: November 29, 2023

A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer.

A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer.

Journal: Clinical & translational immunology

Published: October 12, 2023

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors.

Journal: Frontiers in immunology

Published: December 29, 2022

A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma.

A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma.

Journal: Investigational new drugs

Published: December 05, 2022

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody.

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody.

Journal: Frontiers in immunology

Published: April 27, 2022

A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China.

A Retrospective Study of Lenvatinib Monotherapy or Combined With Programmed Cell Death Protein 1 Antibody in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma in China.

Journal: Frontiers in oncology

Published: October 03, 2021

Showing 1-12 of 14

Last Updated: 09/26/2026